Skub på rekrutteringen til BEXERA.
Patientforening promoverer det på fjæsbogen:
“MDS Foundation, Inc.
Bexmarilimab clinical trial for higher-risk myelodysplastic syndromes
Faron Pharmaceuticals is conducting a randomized placebo-controlled trial of bexmarilimab (BEXERA) in combination with standard of care azacitidine. Newly diagnosed patients 18 or older with higher-risk myelodysplastic syndromes may qualify for this clinical trial. Ask your doctor if this study may be right for you.”
Dertil er der tilknyttet en video af A Zeidan, som omhandler kombinationsbehandlingen med bexmarilimab og azacitidin i BEXMAB-studiet.